Text Size

Reoperation Rates and Disease Costs for Primary Open-Angle Glaucoma Patients in the United States Treated with Incisional Glaucoma Surgery

Randy Craven E., Singh I.P., Yu T.M., Rhoten S., Sadruddin O.R., Sheybani A.


  • 2021
  • Ophthalmology Glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Wilmer Eye Institute, John Hopkins University, Bethesda, MD, United States; The Eye Centers of Racine & Kenosha, Ltd, Racine, WI, United States; Life Sciences, Guidehouse, Inc, San Francisco, CA, United States; Global Medical Affairs, Santen USA, Emeryville, CA, United States; Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO, United States

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.


Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.


Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022